RxDoctor Payments Data

Mauricio Anaya Cisneros, MD

Cardiovascular Disease · North Kansas City, MONPI 1861728982

Payments from drug & device makers

$1,332in general payments, 2019–2025

Across 16 payments — averaging $83.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$1K
  • Pfizer$88
  • Corcept Therapeutics$75
  • Medtronic$71
  • Boston Scientific$25

What the payments were for

  • Travel & lodging$82562%
  • Food & beverage$50738%

General payments by program year

19
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Abbott10$1,073
Pfizer1$88
Corcept Therapeutics1$75
Medtronic(2 entities)3$71
Boston Scientific1$25

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,332 in reported general payments places this provider in the 40th percentile of 391 cardiovascular disease providers in Missouri.

See all cardiovascular disease providers in Missouri

Medicare billing

Part B allowed, 2024
$212,457
Medicare patients
1,944
Services billed
4,364

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban362$374,009
JardianceEmpagliflozin159$149,199
Repatha SureclickEvolocumab103$113,665
XareltoRivaroxaban101$92,752
OzempicSemaglutide48$75,285
EntrestoSacubitril/Valsartan81$64,459
FarxigaDapagliflozin Propanediol67$61,131
Praluent PenAlirocumab15$18,735
Ezetimibe362$7,277
Rosuvastatin Calcium554$6,753
Metoprolol Succinate592$6,582
NexletolBempedoic Acid11$5,937
Ranolazine ErRanolazine65$5,821
Flecainide Acetate63$3,776
Carvedilol373$3,242

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$88$374,009362 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 391 cardiovascular disease providers in Missouri.

Other cardiovascular disease in North Kansas City

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →